Charles River Labs AI Stock Analysis
Charles River Labs (RV6) AI Stock Analysis
Charles River Labs
(BX Swiss:RV6)
No summary available
Charles River Labs Business Overview & Revenue Model
Company Description
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with d...
Charles River Labs Earnings Call Summary
The call was predominantly positive. The company reported stronger-than-expected revenue, earnings, margins, bookings, backlog, and cash flow; raised full-year revenue and EPS guidance; and described improving biopharmaceutical demand, manufacturing momentum, strategic client expansion, and progress in modernization and scientific initiatives. The main challenges were the RMS decline, continued academic and government funding pressure, limited current pricing power, higher interest expense, and the remaining recovery in early-stage biotech activity.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Charles River expects reported revenue decline of 1.5%-2%, organic revenue growth of at least 1.5%, DSA above 2% growth, manufacturing at a mid-single-digit growth rate, and RMS at a low single-digit organic decline; operating margin expansion of approximately 120-150 basis points; non-GAAP earnings per share of $11.35-$11.55, representing 10%-12% year-over-year growth; non-GAAP tax rate of approximately 23%; net interest expense at the upper end of $103 million-$108 million; unallocated corporate costs of approximately 6% of revenue; CapEx of approximately $200 million; and free cash flow of $400 million-$420 million. For the fourth quarter, it expects DSA organic growth at mid-single-digit and manufacturing at high single-digit rates, a modest reduction in the RMS growth rate, continued sequential operating margin improvement of approximately 150 basis points, manufacturing operating margin approaching 40%, and non-GAAP earnings per share growth of approximately 30%-40% year-over-year. For 2027, it expects a gradual improvement from the organic growth rate in 2026, with revenue growth increasing to the targeted 5%-7% range starting in 2028, and operating margin improvement higher than the 75 basis point average through 2030.
Charles River Labs Risk Analysis
Charles River Labs disclosed 41 risk factors in its most recent earnings report. Charles River Labs reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskCharles River Labs Peers Comparison
Overall Rating
MEDP84Outperform
TMO76.9Outperform
LH75Outperform
IQV74Outperform
ICLR69Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $18.59B | 36.21 | 99.76% | ― | 20.35% | 25.24% | |
| 77Outperform | $266.10B | 37.79 | 13.31% | 0.26% | 8.27% | 9.59% | |
| 75Outperform | $30.12B | 30.34 | 11.54% | 0.77% | 6.02% | 19.63% | |
| 74Outperform | $45.34B | 33.00 | 21.82% | ― | 8.88% | 13.11% | |
| 69Neutral | $15.33B | 34.14 | 4.85% | ― | 0.67% | 43.70% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ICLR | Icon Plc | 199.70 | 36.25 | 22.18% | |
| LH | Labcorp Holdings Inc. | 372.23 | 107.04 | 40.37% | |
| TMO | Thermo Fisher Scientific | 717.71 | 139.61 | 24.15% | |
| IQV | IQVIA Holdings | 274.53 | 50.98 | 22.80% | |
| MEDP | Medpace Holdings Inc | 664.77 | 73.45 | 12.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
